Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024

Rhea-AI Summary

Lumos Pharma, Inc. (NASDAQ:LUMO) to announce full year 2023 financial results after market close on March 7, 2024. The company will host a conference call to discuss financial results, clinical progress, and corporate activities.

AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its full year 2023 financial results after market close on Thursday, March 7, 2024. The company will host a conference call and webcast at 4:30 PM ET that day to discuss these financial results and provide an update on clinical and corporate activities. A question-and-answer session will follow the prepared remarks.

Investors and the general public are invited to listen to the conference call. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. The webcast may be accessed through this Webcast Link and may also be found in the “Investors & Media” section of the Lumos Pharma website, under “Events & Presentations.” A replay of the call will be available after the date of the call and may be accessed through the same link above or found on our website.

About Lumos Pharma

Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. The Company was founded and is led by a management team with longstanding experience in rare disease drug development. Lumos Pharma’s lead therapeutic candidate, LUM-201, is a novel, oral growth hormone (GH) secretagogue, seeking to transform the ~$3.4B global GH market from injectable to oral therapy. LUM-201 is currently being evaluated in multiple Phase 2 clinical studies in Pediatric Growth Hormone Deficiency (PGHD) and has received Orphan Drug Designation in both the US and EU. For more information, please visit https://lumos-pharma.com/.

Investor & Media Contact:

Lisa Miller
Lumos Pharma Investor Relations
512-792-5454
ir@lumos-pharma.com

Source: Lumos Pharma, Inc.

FAQ

When will Lumos Pharma announce its full year 2023 financial results?

Lumos Pharma will report its full year 2023 financial results after market close on Thursday, March 7, 2024.

What is the focus of Lumos Pharma's oral therapeutic candidate?

Lumos Pharma is advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials.

How can investors access the conference call and webcast?

Investors can access the conference call by phone through a Registration Link provided by Lumos Pharma. The webcast can be accessed through a Webcast Link on the company's website.

When is the conference call scheduled to take place?

The conference call and webcast are scheduled for 4:30 PM ET on Thursday, March 7, 2024.

Will there be a question-and-answer session during the conference call?

Yes, a question-and-answer session will follow the prepared remarks during the conference call.